CY1121249T1 - Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου - Google Patents
Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτουInfo
- Publication number
- CY1121249T1 CY1121249T1 CY20191100176T CY191100176T CY1121249T1 CY 1121249 T1 CY1121249 T1 CY 1121249T1 CY 20191100176 T CY20191100176 T CY 20191100176T CY 191100176 T CY191100176 T CY 191100176T CY 1121249 T1 CY1121249 T1 CY 1121249T1
- Authority
- CY
- Cyprus
- Prior art keywords
- seq
- stem cell
- antibodies
- antibody against
- cell antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 210000000130 stem cell Anatomy 0.000 title abstract 2
- 230000001681 protective effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 abstract 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012502 diagnostic product Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118022.6A DE102011118022B4 (de) | 2011-06-30 | 2011-06-30 | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| PCT/EP2012/062716 WO2013001065A1 (de) | 2011-06-30 | 2012-06-29 | Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121249T1 true CY1121249T1 (el) | 2020-05-29 |
Family
ID=46384405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100176T CY1121249T1 (el) | 2011-06-30 | 2019-02-11 | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου |
Country Status (18)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| CA3221995C (en) | 2017-02-08 | 2024-05-28 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| CA3108646A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| AU2019318083A1 (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CN116406381A (zh) * | 2020-05-19 | 2023-07-07 | 希望之城 | 工程化抗前列腺干细胞抗原融合蛋白及其用途 |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| WO2024233662A2 (en) * | 2023-05-09 | 2024-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to psca polypeptides |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| NZ337413A (en) * | 1997-03-10 | 2003-02-28 | Univ California | Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer. |
| ES2309012T3 (es) * | 1999-10-29 | 2008-12-16 | Genentech, Inc. | Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca. |
| KR20120125634A (ko) * | 2003-10-16 | 2012-11-16 | 마이크로메트 에이지 | 다중특이적 탈면역화된 ｃｄ3-바인더 |
| EP1753871B1 (en) * | 2004-05-28 | 2015-07-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
| US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| RU2547600C2 (ru) * | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью |
| US20110142811A1 (en) * | 2009-12-16 | 2011-06-16 | Deutsches Krebsforschungszentrum | Measles virus for the elimination of unwanted cell populations |
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
-
2011
- 2011-06-30 DE DE102011118022.6A patent/DE102011118022B4/de not_active Expired - Fee Related
-
2012
- 2012-06-29 PL PL12729996T patent/PL2726507T3/pl unknown
- 2012-06-29 PT PT12729996T patent/PT2726507T/pt unknown
- 2012-06-29 SM SM20190085T patent/SMT201900085T1/it unknown
- 2012-06-29 SI SI201231523T patent/SI2726507T1/sl unknown
- 2012-06-29 ES ES12729996T patent/ES2711978T3/es active Active
- 2012-06-29 HR HRP20190289TT patent/HRP20190289T1/hr unknown
- 2012-06-29 EP EP12729996.4A patent/EP2726507B1/de active Active
- 2012-06-29 EP EP18207370.0A patent/EP3505536B1/de active Active
- 2012-06-29 JP JP2014517736A patent/JP2014528696A/ja active Pending
- 2012-06-29 RS RS20190218A patent/RS58448B1/sr unknown
- 2012-06-29 AU AU2012277784A patent/AU2012277784B2/en not_active Ceased
- 2012-06-29 WO PCT/EP2012/062716 patent/WO2013001065A1/de not_active Ceased
- 2012-06-29 HU HUE12729996A patent/HUE042008T2/hu unknown
- 2012-06-29 TR TR2019/01991T patent/TR201901991T4/tr unknown
- 2012-06-29 US US14/129,933 patent/US9200078B2/en active Active
- 2012-06-29 ES ES18207370T patent/ES2989975T3/es active Active
- 2012-06-29 LT LTEP12729996.4T patent/LT2726507T/lt unknown
- 2012-06-29 DK DK12729996.4T patent/DK2726507T3/en active
-
2017
- 2017-01-12 JP JP2017002983A patent/JP6549622B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-11 CY CY20191100176T patent/CY1121249T1/el unknown
- 2019-06-26 JP JP2019117977A patent/JP6886491B2/ja active Active
-
2021
- 2021-05-13 JP JP2021081553A patent/JP7341185B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2726507B1 (de) | 2018-11-21 |
| EP3505536B1 (de) | 2024-08-07 |
| TR201901991T4 (tr) | 2019-03-21 |
| JP2019193652A (ja) | 2019-11-07 |
| AU2012277784A1 (en) | 2014-02-06 |
| US20140134155A1 (en) | 2014-05-15 |
| DK2726507T3 (en) | 2019-03-11 |
| JP6549622B2 (ja) | 2019-07-24 |
| JP6886491B2 (ja) | 2021-06-16 |
| PT2726507T (pt) | 2019-02-26 |
| DE102011118022A1 (de) | 2013-01-03 |
| JP2021121201A (ja) | 2021-08-26 |
| ES2989975T3 (es) | 2024-11-28 |
| JP2014528696A (ja) | 2014-10-30 |
| ES2711978T3 (es) | 2019-05-08 |
| US9200078B2 (en) | 2015-12-01 |
| JP2017104113A (ja) | 2017-06-15 |
| DE102011118022B4 (de) | 2018-01-18 |
| HUE042008T2 (hu) | 2019-06-28 |
| EP3505536C0 (de) | 2024-08-07 |
| HRP20190289T1 (hr) | 2019-05-03 |
| RS58448B1 (sr) | 2019-04-30 |
| JP7341185B2 (ja) | 2023-09-08 |
| SMT201900085T1 (it) | 2019-05-10 |
| EP3505536A1 (de) | 2019-07-03 |
| LT2726507T (lt) | 2019-04-10 |
| EP2726507A1 (de) | 2014-05-07 |
| WO2013001065A1 (de) | 2013-01-03 |
| AU2012277784B2 (en) | 2015-08-20 |
| PL2726507T3 (pl) | 2019-06-28 |
| SI2726507T1 (sl) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121249T1 (el) | Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ628584A (en) | Ang2-binding molecules | |
| PH12018502623B1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| NZ628382A (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| NZ599405A (en) | Targeted binding agents against b7-h1 | |
| NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| HRP20191095T1 (hr) | Humanizirano anti kallikrein-2 antitijelo | |
| IL258215B (en) | Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody | |
| NZ723369A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| RU2016129517A (ru) | Биспецифические антитела к her2 и способы применения | |
| PE20140448A1 (es) | Moleculas de union biespecificas que se unen a vegf y ang2 | |
| RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака |